Leap Therapeutics stock holds steady as investors await next clinical milestone

Leap Therapeutics stock (ISIN US52195E1029) is trading quietly on the Nasdaq, with a modest market capitalization and a stable price level as of September 21, 2026, as investors watch for the next clinical and regulatory milestones in its immuno-oncology pipeline.

Recent trading and valuation picture

On Nasdaq, Leap Therapeutics stock recently changed hands at a low-single-digit US dollar price, reflecting a market capitalization in the low hundreds of millions of USD as of September 21, 2026; this puts the company firmly in the small-cap biotech bracket and underlines the sensitivity of the share price to trial outcomes and financing decisions.

For investors, one key reference point is the company’s 52-week trading range, which shows that the current price stands clearly below prior peaks but above the lows seen earlier in the year, underscoring that the stock is still volatile and reactive to news despite the quiet tape on September 21, 2026.

Latest reported fundamentals

Leap Therapeutics, Inc. focuses on developing targeted immuno-oncology therapies, and its most recently reported quarterly figures, covering a 2026 interim period within the last nine months before September 22, 2026, show minimal product revenue but ongoing research and development spending; this pattern is typical for a development-stage biotech and means that cash burn and funding runway are central indicators.

According to Leap Therapeutics in its latest quarterly update available via its investor-relations site at Leap Therapeutics, total revenue for the most recent quarter in 2026 was a low single-digit million USD figure, while net loss for the same period remained in the tens of millions of USD, highlighting the gap between current income and the investment needed to advance clinical programs.

In that same 2026 reporting period, cash and cash equivalents at quarter-end were sufficient to fund operations for several quarters but not for multiple years, which puts the focus on potential future capital raises or partnership income; compared with the prior year’s quarter, cash levels declined as cash was deployed into trials and platform development, showing a historical reduction that investors closely monitor.

Analyst and risk context

Analyst coverage of Leap Therapeutics stock remains limited compared with larger biotech peers, but where it exists, recent views in 2026 generally acknowledge the high risk-reward profile: the upside is tied to positive data readouts, while the downside stems from binary clinical and regulatory decisions and the need for external financing.

The core risk factor for Leap Therapeutics as of late September 2026 is that its pipeline is concentrated in a few clinical programs; a negative readout or delay in one of these trials could materially affect the company’s valuation and might force a reassessment of strategy, while a positive result could conversely push the share price toward the upper end of its observed 52-week range.

Stock perspective for retail investors

Given the company’s development-stage profile, Leap Therapeutics stock as of September 21, 2026 trades at a level that already prices in substantial uncertainty: the modest market capitalization relative to the potential peak sales of successful oncology products suggests room for significant moves in either direction once new clinical data or partnership news emerges.

More news and analyses on Leap Therapeutics stock